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Abstract
PARP inhibition can induce anti-neoplastic effects when used as monotherapy or in combination with chemo- or
radiotherapy in various tumor settings; however, the basis for the anti-metastasic activities resulting from PARP inhibition
remains unknown. PARP inhibitors may also act as modulators of tumor angiogenesis. Proteomic analysis of endothelial
cells revealed that vimentin, an intermediary filament involved in angiogenesis and a specific hallmark of EndoMT
(endothelial to mesenchymal transition) transformation, was down-regulated following loss of PARP-1 function in
endothelial cells. VE-cadherin, an endothelial marker of vascular normalization, was up-regulated in HUVEC treated with
PARP inhibitors or following PARP-1 silencing; vimentin over-expression was sufficient to drive to an EndoMT phenotype. In
melanoma cells, PARP inhibition reduced pro-metastatic markers, including vasculogenic mimicry. We also demonstrated
that vimentin expression was sufficient to induce increased mesenchymal/pro-metastasic phenotypic changes in melanoma
cells, including ILK/GSK3-b-dependent E-cadherin down-regulation, Snail1 activation and increased cell motility and
migration. In a murine model of metastatic melanoma, PARP inhibition counteracted the ability of melanoma cells to
metastasize to the lung. These results suggest that inhibition of PARP interferes with key metastasis-promoting processes,
leading to suppression of invasion and colonization of distal organs by aggressive metastatic cells.
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Introduction
Metastatic melanoma is a fatal malignancy that is remarkably
resistant to treatment; however, the mechanisms regulating the
transition from the primary local tumor growth to distant
metastasis remain poorly understood. Metastasis, defined as the
spread of malignant tumor cells from the primary tumor mass to
distant sites, involves a complex series of interconnected events.
Understanding the biochemical, molecular, and cellular pro-
cesses that regulate tumor metastasis is of vital importance. The
metastatic cascade is thought to be initiated by a series of genetic
alterations, leading to changes in cell-cell interactions that allow
the dissociation of cells from the primary tumor mass. These
events are followed by local invasion and migration through
proteolitically modified extracellular matrix (ECM). To establish
secondary metastatic deposits, the malignant cells evade host
immune surveillance, arrest in the microvasculature, and extrav-
asate from the circulation. Finally, tumor cells can invade the local
ECM, proliferate, recruit new blood vessels by induction of
angiogenesis, and then expand to form secondary metastatic foci
[1].
Several key steps in metastatic progression involve tumor-
associated endothelial cells (EC) [2]. Both angioinvasion and
angiogenesis require disruption of endothelial integrity for tumor
cell transmigration across the endothelium, EC migration and EC
access for mitogenic stimulation. An essential step in angioinvasion
and angiogenesis is the disruption of the adherent junctions
between EC. Vascular endothelial cadherin (VE-cadherin; also
known as cadherin 5) is the most important adhesive component of
endothelial adherent junctions [3]; while ectopic expression of VE-
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cadherin in malignant melanoma cells confers this tumor the
capability to form vessel-like structures that contributes to the lack
of efficient therapeutic strategies and increases the risk of
metastatic disease [4].
Epithelial-mesenchymal transition (EMT) is a trans-differentia-
tion characterized by decreased epithelial markers such as E-
cadherin[5]. EMT is a dynamic process resulting in the acquisition
of cell motility with decreased adhesive ability for body
organization that includes embryonic development and wound
healing. Currently, EMT is thought to be a key step in the process
of cancer metastasis [6]. Molecular markers of EMT include E-
cadherin down-regulation, responsible for the loss of cell-cell
adhesion, up-regulation of matrix-degrading proteases and mes-
enchymal-related proteins such as vimentin and N-cadherin, actin
cytoskeleton reorganization, and up-regulation and/or nuclear
translocation of transcription factors underlying the specific gene
program of EMT, such as b-catenin and members of the Snail1
family [6].
The nuclear protein PARP-1, known to function as a DNA
damage sensor and to play a role in various DNA repair pathways,
has recently been implicated in a broad variety of cellular
functions, including transcriptional regulation [7]. PARP inhibi-
tors exhibit antitumor activity in part due to their ability to induce
synthetic cell lethality in cells deficient for homologous recombi-
nation repair [8,9,10,11]. PARP inhibitors also possess anti-
angiogenic properties [12,13,14,15], and recently, our group
reported that PARP inhibition results in the down-regulation of
Snail1 by accelerating the degradation of this protein [16]. In the
present study we aimed to address the potential of PARP
inhibition as modulators of metastasis [16].
The results presented here indicates that PARP inhibition,
through down-regulation of the intermediary filament vimentin in
both endothelial and melanoma cells, led to a reversion of
mesenchymal phenotype in both cell types and prevented
malignant melanoma cells from developing vasculogenic mimicry.
As monotherapy, PARP inhibition displayed an anti-metastatic
effect in a model of murine melanoma. Moreover, we identified
vimentin as an upstream modulator of EMT: forced expression of
vimentin was sufficient to induce tumor cell transformation
through the ILK/GSK-3b signaling axis. The ability of PARP
inhibition to modulate vimentin levels (and hence EMT), the
interference with vasculogenic mimicry, and the modulation of
endothelial plasticity allowed PARP inhibitors to exert a multi-
faceted antimetastatic effect to counteract the progression of
malignant melanoma.
Results
PARP inhibition induced down-regulation of vimentin
expression in endothelial cells
A number of reports from various laboratories, including ours,
have identified a novel and unexpected effect of PARP inhibitors
on angiogenesis, raising the possibility that PARP inhibitors may
be useful as anti-angiogenic agents [13,17]. In our present study,
we disrupted PARP activation in HUVECs in an attempt to
elucidate the mechanism by which PARP-1 influences endothelial
cell dynamics. We have previously shown that PARP inhibitors
reduced angiogenesis both in vitro and in vivo ([13] and Figure S1).
To further characterize this effect of PARP inhibition on
endothelial cell plasticity, we performed a proteomic analysis
using primary HUVEC in the presence or absence of the PARP
inhibitor DPQ (Figure 1A, Figure 2 and Figure S2). The
expression levels of a number of proteins were altered following
PARP inhibition, as detected by 2D DIGE electrophoresis (Figure
S2) and mass spectrometry analysis (Figure 1A, Figure 2). A
statistically significant down-regulation of vimentin (a class III
intermediary filament), tropomyosin alpha-4 chain (involved in
stabilizing actin filaments), endoplasmin (a molecular chaperone
involved in processing and transport of secreted proteins),
mitochondrial ATP synthase ATPB5, protein disulfide isomerase
PDIA6, heat-shock 70 kD protein-5 (glucose-regulated protein,
78 kD), heat shock protein 90 kDa alpha (cytosolic), class B
member 1, and HSP90AB1 occurred following PARP inhibition.
An increase in the expression of the mitochondrial heat shock
protein HSPD1 was also observed after PARP inhibition.
Due to its important role in the biology of endothelial cells, we
focused our study on vimentin, the main structural protein of inter-
mediary filaments. It has been reported that vimentin can be
targeted for tumor inhibition due to its specific up-regulation in
tumor vasculatures [18,19]. To confirm the results of our proteomic
analysis, we performed western blot in HUVEC either treated with
DPQ (right) or left untreated. In Figures 1B and 1C, western blot
and indirect immunofluorescence analysis indicated that vimentin
expression was down-regulated in HUVEC cells treated with DPQ.
Figure 1B and 1D show that PARP inhibition affected not only
vimentin levels but also Snail1 and VE-cadherin protein and
mRNA levels.
Endothelial to mesenchymal transition (EndoMT) is a process
by which endothelial cells disaggregate, change shape, and migrate
into the surrounding tissue. The process of endoMT is character-
ized by the loss of endothelial cell markers, such as vascular
endothelial VE-cadherin, and the expression of mesenchymal cell
markers, such as vimentin and Snail1 [20]. Endothelial cell
migration was strongly inhibited by PARP inhibition (Figure 1E).
These results suggest that PARP inhibition prevented the
acquisition of a mesenchymal phenotype by endothelial cells.
Interplay between vimentin and PARP-1 modulates the
expression and activity of proteins involved in EMT
Vimentin is a well-known marker of EMT, which is a hallmark
of primary tumor progression to a metastatic phenotype. We
tested the impact of vimentin down-regulation (induced by PARP
inhibition or vimentin silencing) on EMT differentiation in various
melanoma cell lines and in endothelial cells. One major event
induced by PARP inhibition, in the process of EMT is the up-
regulation of E-cadherin expression through the inactivation of the
transcription factor Snail1. Snail1 and vimentin levels were both
down-regulated following PARP inhibition, indicating a disruption
EMT in the absence of PARP activation (Figure 3A in G361 cells
and Figure S3B in B16-F10 cells). Down-regulation of PARP
Author Summary
Metastasis is the spread of malignant tumor cells from
their original site to other parts of the body and is
responsible for the vast majority of solid cancer-related
mortality. PARP inhibitors are emerging as promising
anticancer therapeutics and are currently undergoing
clinical trials. It is therefore important to elucidate the
mechanisms underlying the anti-tumor actions of these
drugs. In our current study, we elucidated novel anti-
neoplastic properties of PARP inhibitors that are respon-
sible for the anti-metastatic effect of these drugs in the
context of malignant melanoma. These effects appear to
be the result of PARP-1’s ability to regulate the expression
of key factors, such as vimentin and VE-cadherin, involved
in vascular cell dynamics and to limit pro-malignant
processes such as vasculogenic mimicry and EMT.
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activity was confirmed in G361 following H2O2 treatment as a
positive control of PARP-1 activation and poly(ADP-ribose) (PAR)
synthesis (Figure S4). Vimentin and Snail1 mRNA levels were
decreased after PARP inhibition (Figure 3C and Figure S3C). In
Figures 2B and Figure S3A, indirect immunofluorescence showed
that vimentin expression was down-regulated in melanoma cells
treated with DPQ or KU0058948 (G361 cells, Figure 3B) or PJ-34
(B16-F10 cells, Figure S3A). Using two different luciferase reporter
plasmids under the control of a Snail1 responsive sequence and the
E-cadherin promoter, we found that PARP inhibition affected
negatively the activation of Snail1 and activated the expression of
the E-cadherin promoter (Figure 3D and Figure S3D). Wound
healing experiments also revealed decreased wound closing
following treatment with a PARP inhibitor, PJ-34 (Figure 3E).
We have also evaluated the effect of both PARP-1 and vimentin
silencing on the expression of Axl, a key determinant of cell
migration and EMT promotion [21]. Following PARP-1 silencing
in HUVEC or G361 cells, the EMT marker Snail1 decreased
while E or VE-cadherin were upregulated (Figure 4A and 4B
respectively). Interestingly, Axl expression was also down-regulat-
ed in parallel with decreased levels of vimentin. Vimentin
knockdown also caused a global alteration in the expression of
EMT markers. Under these conditions, Axl levels were decreased
(Figure 4A and 4B), suggesting that vimentin down-regulation was
sufficient to drive tumor cells toward an epithelial state.
We next sought to determine if alterations in vimentin levels were
sufficient to alter or reverse EMT progression. Vimentin is known to
positively influence tumor cell migration. To test the impact of
vimentin expression on cell migration and invasion we performed
either silencing or over-expression in endothelial and melanoma
cells. Following vimentin knockdown, wound healing closure in
HUVEC cells was significantly diminished (Figure 4C) while its
over-expression increased wound healing efficiency (Figure 4D).
The same approach was used in B16F10 melanoma cells where
over-expression of vimentin increased significantly cell migration
(Figure 4E). Nonetheless, inhibition of PARP had a less impact on
cell migration after vimentin over-expression, suggesting that the
levels of vimentin were implicated in the effect of PARP inhibition
on cell motility (Figure 4E), although a multifactorial mechanism for
downstream effect of PARP inhibition could not be excluded.
To further confirm the role of vimentin in PARP-inhibitor-
induced impaired cell migration we decided to analyze the effect of
vimentin over-expression and PARP inhibition in a well-
established model of epithelial cells, MDCK, that undergo EMT
Figure 1. PARP inhibition down-regulates vimentin expression and inhibits endothelial-to-mesenchymal transition in HUVECs. Cell
extracts from HUVEC either treated with vehicle or 40 mM DPQ were subjected to 2D electrophoresis as described in Materials and Methods. Image
analysis software (DeCyder) indicated that seven proteins exhibited decreased expression in HUVEC treated with DPQ compared to untreated cells.
Proteins were identified using MALDI-TOF. Spots labeled with arrows indicate proteins that were identified by mass spectrometry (see Figure 2). (A)
The spot with the arrow is vimentin. (B) PARP inhibition reduced the expression of both vimentin and Snail1 and up-regulated VE-cadherin in human
endothelial cells (HUVEC) as determined by immunoblotting, indirect immunofluorescence (C), and mRNA levels (D). PARP inhibition decreased
HUVEC cell migration (E). (**P,0.01, ***P,0.001 PARP inhibitor groups versus DPQ).
doi:10.1371/journal.pgen.1003531.g001
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after hepatocyte growth factor (HGF) treatment, including fast
movement and circularity (scattering) [22]. The trajectories of cell
migration were determined under video-microscopy and analyzed
using MetaMorph image analysis software. Global trajectories
after expression of GFP-vimentin in the presence or absence of
PARP inhibitor and HGF were determined. Treatment with the
PARP inhibitor PJ-34 or olaparib resulted in decreased cell
motility in cells transfected with empty GFP vector (Figure 4F).
Vimentin expression increased cell motility (Figure 4F, right), and
PARP inhibition was unable to prevent this increase, suggesting
that vimentin down-regulation is needed for the effect of PARP
inhibition in reversing the EMT phenotype.
To characterize more in-depth the implications of vimentin
expression in the context of EMT, we expressed GFP-vimentin in
both a human melanoma cell line (Figure 5A) and a human breast
tumor cell line with an epithelial phenotype (MCF7) (Figure 5B
and 5C); MCF7 cells were chosen due to the lack endogenous
vimentin expression compared with melanoma G361 cells
(Figure 5A, G361 cells and Figure 5B and 5C, MCF7 cells).
GFP-vimentin over-expression alone induced a mesenchymal
phenotype characterized by Snail1 up-regulation, loss of E-
cadherin, increased pGSK-3b (inactive form) and b-catenin
expression (Figure 5A, 5B and 5C).
The most remarkable effect of PARP or vimentin silencing
observed in our model was the down-regulation of ILK and GSK-
3b (Figure 4A and 4B). In order to get mechanistic information on
the interaction between vimentin over-expression and the activa-
tion of EMT signaling pathway, we focused in the axis ILK/GSK-
3b, which plays a central role in EMT commitment, upstream of
Snail1. Inhibition of GSK-3b was achieved by LiCl treatment
while its activation was driven by silencing the kinase, ILK, which
is the upstream inhibitory kinase for GSK-3b (Figure 5, central
panel). Specifically, inhibition of GSk-3b (which was confirmed by
an increase in the level of inhibitory phosphorylation of GSK-3b
at Ser9) with LiCl, activated EMT and resulted in E-cadherin
down-regulation, Snail1 accumulation and increased levels of b-
catenin (Figure 5B); concomitantly, E-cadherin was down-regu-
lated following GSk-3b inhibition by LiCl (Figure 5B) or
exogenous expression of vimentin (Figure 5).
GSk-3b activation is achieved through the silencing of its upstream
inhibitor integrin-linked kinase (ILK). ILK knockdown resulted in Snail1
down-regulation and increased E-cadherin expression (Figure 5C).
Interestingly, exogenous vimentin expression completely prevented
siILK-induced E-cadherin up-regulation and partially prevented the
reduction of Snail1 expression. These results suggested that vimentin,
when over-expressed, is sufficient to drive the phenotypic changes
Figure 2. Proteins differentially expressed and identified by mass spectrometry analysis in HUVEC. The level of expression of various
proteins in HUVEC was altered following PARP inhibition as determined by 2D-DIGE, and the proteins were positively identified using mass
spectrometry analysis. Of particular interest for this study was vimentin, the major structural protein of intermediary filaments (spot 1). Expression of
this protein was decreased in HUVEC following PARP inhibition. The proteins were identified by MALDI-TOF. Sequence coverage (%) and number of
peptides were identified with = 1% FDR (false discovery rate cut-off against decoy-concatenated randomized database). Coverage and score was
determined using the MASCOT algorithm. The average ratio of protein expression between the control and cells treated with the PARP inhibitor DPQ
was determined in HUVEC.
doi:10.1371/journal.pgen.1003531.g002
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associated with a mesenchymal cell status, depending on the activation
of GSk-3b, whose inhibition accentuated vimentin-induced changes,
while its activation (following ILK-silencing), abolished vimentin-
induced E-cadherin decrease and Snail1 accumulation (Figure 5C).
PARP inhibition suppresses vasculogenic mimicry in
malignant melanoma cells
The formation of patterned networks of matrix-rich tubular
structures in three-dimensional culture is a defining characteristic
of highly aggressive melanoma cells. It has been demonstrated that
aggressive melanoma cells in which VE-cadherin was repressed,
could not form vasculogenic-like networks [23], suggesting that
tumor-associated misexpression of VE-cadherin (observed in
melanoma cells) is instrumental in allowing endothelial cells to
form vasculogenic networks. We measured VE-cadherin protein
levels in B16-F10 cells after treatment with the PARP inhibitor PJ-
34 or KU0058948. VE-cadherin expression was strongly down-
regulated following PARP inhibition. We tried to confirm this
Figure 3. PARP inhibition inhibits the acquisition of an EMT phenotype in malignant melanoma cells. Human melanoma G361 cells and
murine B16- F10 melanoma cells (Figure S3) were used for these experiments. Cells were treated with either DPQ (40 mM), PJ-34 (10 mM) or
KU0058948 (100 nM) for 22 hours. IF, western blot or qPCR assays were performed to evaluate the effects of PARP inhibition on EMT markers. PARP
inhibition reduced the expression of vimentin and Snail1 and up-regulated E-cadherin in human melanoma cells as determined by immunoblotting
(A), indirect immunofluorescence (B), and mRNA levels (C). (*P,0.05, ***P,0.001, PARP Inhibitor groups versus the control). b-actin was used as an
internal control for protein loading. (D) Snail1 and E-cadherin promoter activity are regulated by PARP inhibitors. Luciferase activity was determined
after transfecting the constructions into G361 cells. Firefly Luciferase was standarized to the levels of Renilla Luciferase. Cells were cotransfected with
0.5 mg renilla as a transfection control and 0.5 mg of Snail1 or E-cadherin using jetPEI cationic polymer transfection reagent according to the
manufacturer’s instructions. Cells were compared in the presence or absence of serum (***P,0.001 control versus PJ-34). The expression of both
Firefly and Renilla luciferase was analyzed 48 h after transfection. Cloning of the human Snail1 promoter (2869/+59) into pGL3 basic (Promega) was
described previously (41). The E-Cadherin promoter was cloned into pGL3-basic (Promega) to generate pGL3-E-cadherin (2178/+92). (E) Inhibitory
effect of PARP on B16F10 motility. Treatment with the PARP inhibitor PJ-34 (10 mM) decreased cell migration in vitro. Migration was quantified as
distance between Wound Healing limits (*** P,0.001 control versus DPQ).
doi:10.1371/journal.pgen.1003531.g003
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result by indirect immunofluoresce of VE-cadherin, however the
protein was barely detected, as was the case for the protein in
western blot (Figure 6A). Phosphorylation of VE-cadherin has
been shown to correlate with loss of function of VE-cadherin and
increased vascular permeability [24], as is the case for pseudo
vessels during VM. PARP inhibition was able to impact negatively
on the levels of both total and phosphorylated VE-cadherin,
which, indeed, had a membrane and cytoplasmic distribution
(Figure 6A). The consequences for the down-regulation of both
total and phosphorylated VE-cadherin by PARP inhibitors during
VM are now being investigated in our laboratory.
VM was measured in vitro using B16F10 cells cultured in matrigel
coated plates (Figure 6B). All markers of VM structure formation
(covered area, tube length, branching points and loops) were
significantly decreased after inhibition of PARPwith PJ-34 (Figure 6C).
PARP inhibition protects against lung-metastasis of
murine melanoma cells
We next aimed to examine the effect of PARP inhibition on
melanoma tumor growth of cells subcutaneously implanted in
C57BL/6 mice. Mice were treated every two days with 15 mg/kg
(i.p.) of the PARP inhibitor DPQ or vehicle. A significant
difference in tumor growth was found after 14 days of tumor
implantation in the DPQ-treated group compared to the control
(Figure 7 and Figure S5A).
To evaluate the direct effects of the PARP inhibitor DPQ on
tumor metastasis, we used a well-characterized model of exper-
imental lung metastasis [25]. Experimental metastasis model
provide several advantages for investigation. The time course for
model maturity is generally rapid, the biology of metastasis is
reproducible and consistent, and we control de number and type
of cells that are introduced to the circulation [26]. B16-F10 cells
were tail vein injected into mice, and the mice were then treated
with 15 mg/kg of the PARP inhibitor DPQ or vehicle three times
per week over a three-week period. Tail vein injection results
primarily in pulmonary metastases. Photon emission was acquired
every two days. Seven days after B16-F10 cell injection, a photon
signal was already detected in the lungs (Figure 7B), and DPQ
treatment significantly suppressed lung metastasis compared to the
control throughout the duration of the experiment (21 days).
Similar results were obtained using the clinically relevant PARP
Figure 4. PARP-1 or vimentin is sufficient to reverse EMT and confer increased cell motility. (A) Melanoma (G361) and endothelial
(HUVEC) (B) cells were silenced for PARP-1 or vimentin and the expression levels of Axl, E-/VE-cadherin, Snail1, ILK, b-catenin, GSK-3b, PARP-1, and
vimentin were determined by immunoblot. (C) HUVEC were silenced for vimentin and wound healing was measured. After over-expression of
vimentin wound healing closure was measured in HUVEC cells (D) or B16-F10 (E). (F) Cell migration was analyzed in epithelial cell line Madin Darby
canine kidney (MDCK) cells transfected with either GFP or GFP-vimentin using video-microscopy and MetaMorph Image Analysis software. While
vimentin was able to increase the length of the trajectories in the absence or presence of hepatocyte growth factor (HGF), treatment with PARP
inhibitor resulted in a sustained reduction in cell motility (*P,0.05 PJ-34 or olaparib versus control).
doi:10.1371/journal.pgen.1003531.g004
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inhibitor olaparib (Figure S6). Metastatic foci were also detected in
other organs upon mice autopsy. These organs included the liver,
kidney, spleen, gut, stomach and heart (Figure S5B). In all cases,
the incidence of metastatic foci was reduced compared to lung
metastasis. DPQ-treated mice exhibited a decreased incidence of
extra-pulmonary metastasis compared to the control. Pathologic
analysis of the lungs showed a decrease in size and number of
metastatic foci (more than 80%) after DPQ treatment (Figure 7C)
that was accompanied by a reduced number of tumor vessels in
both primary subcutaneous tumors and lung metastasis
(Figure 7D), suggesting that the anti-angiogenic effect of PARP
inhibition may be involved in the observed reduction in metastatic
progression. Apoptotic and mitotic rate were not significantly
different in tumors derived from DPQ-treated or untreated mice
(Figure S7). To investigate in vivo the effect of PARP inhibition on
the expression of Snail1 and E-cadherin, we performed immuno-
histochemistry for these EMT markers in metastatic lung tumors
(Figure 7E). We observed that Snail1 was highly expressed in the
vessels of tumors derived from the untreated group. This
expression exhibited both nuclear and cytoplasmic distribution
as previously reported [27]. Metastatic lung tumors derived from
DPQ-treated mice displayed reduced expression of Snail1 as well
as an increase in E-cadherin expression, similar to the results
obtained in cultured melanoma cells. These data indicate that the
in vivo expression of EMT markers within tumors is also reduced
following treatment with PARP inhibitor. We also performed a
Kaplan Meyer curve to compare the mortality of both groups of
mice, and we observed a statistically significant difference in the
survival rate from,4 weeks in the untreated group to.8 weeks in
the DPQ-treated mice (Figure 7F). Survival of mice injected with
B16-F10 cells stably expressing shRNA targeting PARP-1
(Figure 7G), was also significantly increase.
Human melanoma tissue array
To determine the correlation between PARP-1 expression and
disease progression in human melanoma, we used IHC to analyze
the levels of vimentin, PARP-1, Snail1, E-cadherin and MITF in
nodular and metastatic melanoma frozen biopsies. Vimentin was
expressed in all biopsies derived from both nodular and metastatic
melanoma; however, the level of expression was elevated in
nodular melanoma, which is the initial stage of the disease. PARP-
1 expression was positively correlated with vimentin expression,
Figure 5. Interaction between vimentin over-expression and the activation of EMT signaling pathway. (A) Over-expression of vimentin
in G361 cells. (B) Forced expression of vimentin drives human breast tumor epithelial cells (MCF7) to a mesenchymal phenotype through the integrin-
linked-kinase/GSK-3b axis. 5 mM LiCl was used to inhibit GSK-3b, as detected by the accumulation of beta-catenin. (C) ILK was knocked down to
analyze the significance of the interaction between vimentin and ILK in promoting the transition to a mesenchymal phenotype.
doi:10.1371/journal.pgen.1003531.g005
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suggesting an association between the in vivo expression of both
proteins (Figure S8, Table S1). Expression of the Snail1 and
microphthalmia-associated transcription factor (MITF), which is a
melanocyte marker, is also increased in metastatic melanoma.
Interestingly, nodular melanoma did not express Snail1 while 40%
of metastatic melanoma samples displayed Snail1 expression. Loss
or reduction of E-cadherin and increased expression of EMT
markers is frequently associated with the development of an
invasive phenotype in cancer. Expression of E-cadherin in normal
melanocytes is significantly reduced during the initial steps of
melanoma progression [28]; however, elevated levels of E-
cadherin are found at advanced stages of the disease [29]. E-
cadherin expression was similar in both nodular and metastatic
melanoma (Table S1), which is in agreement with previous
publications. These findings suggest that in human melanoma,
there is a complex interconnection between the expression levels of
various disease markers and the expression of PARP-1, although
we have detected a strong correlation between vimentin and
PARP-1 expression (Figure S8).
Discussion
PARP inhibitors are a novel and important class of anticancer
drugs, and there are now more than 40 clinical trials that are
ongoing or in development to study the effectiveness of PARP
inhibitors in the treatment of various cancers. Given the enormous
interest in this target, it is important to understand the underlying
mechanisms by which PARP-1 and other PARPs function in
tumor cell biology. Until recently, the development of PARP-1
inhibitors has focused almost exclusively on the function of this
enzyme in DNA repair. Emerging literature, however, indicates
other activities of PARP-1 that may explain the in vivo potency of
some PARP-1 inhibitors that cannot be entirely attributed to their
apparent in vitro activity and that could provide additional targets
for anti-cancer therapies. In addition to its direct role in DNA-
damage recognition and repair, PARP-1 can regulate the function
of several transcription factors, including p53 and NF-kB. In the
context of certain cancers, PARP-1 interacts with the transcription
factors HIF1 [13] and Snail1 [16]. The mechanisms underlying
Figure 6. Vasculogenic mimicry is reduced by PARP inhibition in cells and in xenogafts of malignant melanoma. (A) Western-blot and
immunofluorescence of VE-cadherin and pVE-cadherin in B16-F10 cells treated with PJ-34 or KU0058948. (B, C) B16-F10 cells were cultured on
polystyrene-treated culture slides and treated with the PARP inhibitor PJ-34 at 20 mM or left untreated. Following treatment, pictures were taken and
analyzed using Wimasis image analysis software. ‘‘Branching points’’: crossroads from at least three ‘‘branches’’. ‘‘Loops’’: Closed areas surrounded by
cells. Four independent experiments were performed (*P,0.05; **P,0.01).
doi:10.1371/journal.pgen.1003531.g006
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the effects of PARP inhibition on vascular plasticity and metastasis
remain relatively unknown. Our current study identifies PARP-1
as a pivotal modulator of the molecular and functional changes
characteristic of EndoMT (involved in the loss of function of
tumor-associated vessels) and of the phenotypic switch that
facilitates the acquisition of pro-metastatic capacities by tumor
cells. Proteomic analysis of endothelial cells that have been treated
with a PARP inhibitor identifies the intermediary filament protein
vimentin as a target of PARP inhibition. Intermediary filaments
such as vimentin and keratins are known to play non-mechanical
roles in protein trafficking and signaling (reviewed in [30]), which
in turn influence cellular processes such as cell adhesion and
polarization. Vimentin is abundantly expressed by mesenchymal
cells and plays a critical role in wound healing, angiogenesis and
cancer growth. Vimentin has also been described as a tumor-
specific angiogenesis marker, and targeting endothelial vimentin in
a mouse tumor model significantly inhibited tumor growth and
reduced microvessel density [31].
Vimentin is both an EMT and EndoMT marker and is also
over-expressed in tumor samples compared to normal tissues. This
protein also contributes to tumor phenotype and invasiveness
[18,19]. Our findings indicate that PARP inhibitors reduce the
metastatic potential of melanoma cells, at least in part, through
their ability to down-regulate vimentin expression.
Vimentin expression has been shown to be transactivated by b-
catenin/TCF and thus increasing the tumor cell invasive potential
[19]. It has been shown that NF-kB, a key protein regulating the
immune and inflammatory process, also plays an important role in
regulating EMT process and its inhibition in the mesenchymal
cells reversed the EMT process, suggesting the importance of NF-
kB in both activation and maintenance of EMT [32]. Since
vimentin is over expressed during EMT process, and NF-kB being
Figure 7. Decreased melanoma-induced lung metastasis following PARP inhibition. (A) Mice were inoculated with the murine melanoma
cell line B16-F10-luc. Localization and the intensity of luciferase expression were monitored by in vivo bioluminescence imaging (dpi, days post cells
injection). At the bottom of Figure A two lungs from vehicle (left) or DPQ (right) treated mice are shown. Lungs were extracted to analyze the number
of melanoma foci. Quantification of luciferase activity over time shows the average light (photons) emission in photons/s (B) (**P,0.01; ***P,0.001
versus DPQ). (C) The number of metastatic foci/lung were counted macroscopically (***P,0.001). (D) Angiogenesis was measured using a specific
endothelial cell marker (tomato lectin) and measured as blood vessels per mm2 in tumor sections of lung metastasis (Columns, mean 6 SE. *P,0.05,
with respect to control and DPQ–treated mice. (E) Immunohistochemistry staining of Snail1 and E-Cadherin in lung metastasis and quantitation using
ImageJ , colour deconvolution plugin (F and G) Kaplan-Meyer survival curve shows the survival advantage of DPQ-treated mice following
intravenous tail injection of melanoma cells as previously described in mice treated with DPQ (F) or injected with B16F10 stably silenced for PARP-1
(G) (** P,0. 01).
doi:10.1371/journal.pgen.1003531.g007
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one of the transcription factors binding to vimentin promoter, it
would be tempting to speculate that this over-expression of
vimentin is a result of activated NF-kB in cancer cells. Also,
TGFb1 response element was found within the activated protein
complex-1 region of the vimentin promoter and was involved in
regulation of vimentin expression in myoblasts and myotubes [33].
Interestingly, ADP-ribosylation of Smad proteins by PARP-1 has
been shown to be a key step in controlling the strength and
duration of Smad-mediated transcription [34]. Regulation of
vimentin levels by PARP inhibition may also involve other
transcription factor such as Snail1 and HIF-1/2.
Our results also reveal that vimentin levels are not merely a
hallmark of EMT. While silencing of vimentin in melanoma cells
can reverse the EMT phenotype, in part by promoting down-
regulation of the protein kinase Axl that is involved in cell motility,
forced expression of vimentin in tumor cells lacking this protein is
sufficient to trigger the switch from epithelial to mesenchymal
phenotype. GSK-3b is an upstream regulator of key factors
involved in EMT such as Snail1 and b–catenin. We hypothesized
that vimentin may be involved in the modulation of this upstream
regulator of EMT. Indeed, vimentin expression potentiated LiCl-
(a GSK-3b inhibitor) induced EMT (Figure 5B) and counteracted
the inhibitory action of ILK-silencing (leading to GSK-3b
activation) in the context of EMT (Figure 5C). Mechanical signals
can inactivate GSK-3b resulting in stabilization of b-catenin.
Intermediate filaments are important in allowing individual cells,
tissues and organs to cope with various types of stress, and they
play a significant role in the mechanical behavior of cells [35]. It is
possible that the signaling pathway that integrates PARP
activation with altered vimentin expression and fluctuations in
GSk-3b activity could be related to the capability of PARP
inhibitors to inactivate AKT signaling [36], which would result in
GSk-3b activation and the modulation of its downstream
signaling, ultimately resulting in the reversal of EMT.
Vasculogenic mimicry, as a de novo tumor microcirculation
pattern, differs from classically described endothelium-dependent
angiogenesis. This is a unique process characteristic of highly
aggressive melanoma cells found to express genes previously
thought to be exclusively associated with endothelial cells and is
characteristic of aggressive melanoma tumor cells. HIF-1a and
HIF-2a, transcription factors that are stabilized during conditions
of oxygen depletion (hypoxia), are the master regulators of VE-
cadherin. HIF-mediated transcriptional regulation during hypoxia
is critical as this process induces genes that are essential for tumor
cell adaptation to the stress of oxygen depletion. As a result, the
expression of HIF target genes is associated with increased
malignancy. Although the expression of VE-cadherin is not
hypoxia-regulated, HIF-2a, but not HIF-1a, activates the VE-
cadherin promoter by binding to the HRE during normoxic
conditions [37]. HIF-2a expression is associated with developing
endothelium, proper vascular development and increased tumor
malignancy [38,39], raising the possibility that it may be an
important protein that functions in the induction of tumor cell
plasticity.
Using a mouse model of melanoma lung metastasis, we also
present in vivo evidence indicating that targeting PARP strongly
reduces metastatic dissemination of melanoma cells, at least in part
through inducing a reduction in tumor microvessel density along
with changes in the expression pattern of EMT markers (Snail1,
vimentin and E-cadherin) within the tumor.
Snail1 is a master regulator of EMT, and the activation of this
protein can mediate tumor invasiveness through the transcrip-
tional repression of E-cadherin expression. Regulating the activity
of E-cadherin repressors represents a potentially beneficial strategy
to fight cancer progression, and PARP-1 inhibitors accomplish this
function by interfering with Snail1 activation.
Results from human tissue arrays of melanoma suggest a
complex interaction between PARP-1 expression and melanoma
progression. It is difficult to verify EMT experimentally in vivo due
to the reversible and dynamic nature of the process. Although
melanoma cells are not epithelial in nature, the EMT for this
tumor is well characterized and the relevance of the cadherin
switch has been previously described using several experimental
approaches, demonstrating that melanoma cell lines transfected
with N-cadherin are morphologically transformed from an
epithelial-like shape to a fibroblast-like shape [37]. Adenoviral
re-expression of E-cadherin in melanoma cells down-regulates
endogenous N-cadherin and reduces the malignant potential of
these cells [37].
Globally, our study shows that PARP inhibition is perturbing
metastatic transformation at least at three levels (Figure 8): i)
decreasing abnormal tumor angiogenesis through its ability to
counteract Endo-MT; ii) preventing from acquisition of EMT and
iii) limiting vasculogenic mimicry in melanoma cells.
Over the past few years, PARP has emerged as a strong and
effective target for first line anticancer therapy. Due to its ability to
regulate a number of cellular functions (from DNA repair to cell
death and transcription), inhibition of PARP may affect multiple
facets of tumor metabolism. These findings strongly indicate that
several novel activities of PARP-1 may contribute to the effects of
anti-cancer therapy targeting this protein by interfering with
tumor physiology and the tumor microenvironment. Given these
findings, it is of vital importance that we elucidate mechanisms
regulating novel functions of PARP-1 and poly (ADP-ribose) in
tumor biology so that PARP inhibitors can ultimately make the
transition to routine clinical use.
Materials and Methods
Cell culture
Human umbilical vein endothelial cells (HUVEC) were cultured
in EGM-2 Endothelial Cell Growth Medium-2 (LONZA). Cells
were subjected to experimental procedures within passages 3–6.
B16-F10-luc-G5 cells stably expressing plasmids pGL3 control
(SV40-luc) (Promega) and pSV40/Zeo (Invitrogen). Human
(G361), murine (B16-F10) malignant melanoma cells and breast
cancer (MCF7) cells were cultured in DMEM containing 10%
fetal bovine serum, 0.5% gentamicin (Sigma, St. Louis, MO), and
4.5% glucose. All cells were cultured at 37uC (5% CO2). The
tumor cell lines have been developed as described in detail
previously [40]. Melnikova et al. [41] found that unlike human
melanomas, the murine melanomas cell lines did not have
activating mutations in the Braf oncogene at exon 11 or 15. All
of the cell lines also expressed PTEN protein, indicating that loss of
PTEN is not involved in the development of murine melanomas.
This B16-F10 cell has previously been shown to be sensitive to
stable depletion of PARP-1 in vivo melanoma growth [17].
Previous publication from our lab in G361 cells show similar
results [16]. Cells were treated with the PARP inhibitors 3,4-
dihydro-5-[4-(1-piperidinyl)butoxyl]-1(2H)-isoquinolinone (DPQ),
[N-(6-Oxo-5,6-dihydro-phenanthridin-2-yl)-N,N-dimethylaceta-
mide] (PJ-34) (Alexis Biochemicals, San Diego, CA) (as described
[42], KU0058948 (as we shown in previous publications [16] or
Olaparib (KU0059436, Selleckchem) for 22 hours. For capillary-
like formation assays, 25 mL of Matrigel (BD Biosciences) were
spread onto eight-chamber BD Falcon glass culture slides (BD
Biosciences) or onto 96-well plates. Cells were seeded at 2.56104
cells per well (high density) in eight-chamber slides and at 56103
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cells per well (low density) in 96-well plates and maintained in
RPMI supplemented with 1% FBS [13].
Western blot, quantitative RT-PCR and luciferase reporter
gene assay
These assays were performed according to previously published
methods [13]. Primary antibodies used in these studies consisted of
vimentin and VE-cadherin (mouse monoclonal), E-cadherin
(rabbit polyclonal) (Santa Cruz Biotechnology), Snail1 and pVE-
cadherin (rabbit polyclonal) (Abcam), ILK (rabbit monoclonal)
(Millipore), Axl (rabbit polyclonal), total-GSK-3b (mouse mono-
clonal) and pGSK-3b (rabbit monoclonal) (Cell Signaling), b-
catenin (mouse monoclonal) (BD Transduction Laboratories),
PARP-1 (monoclonal) (Alexis) as well as b-actin (Sigma Aldrich).
Quantitation of western blots was performed using Quantity One
software analysis and all densitometries were normalized for
loading control (Table S2).
Luciferase activity was determined after transfecting the cons-
tructions into the B16-F10 cells. Firefly Luciferase was standard-
ized to the value of Renilla Luciferase. Cells were co-transfected
with 0.5 mg renilla as control of transfection together with 0.5 mg
of the Snail or E-cadherin plasmid using jetPEI cationic polymer
transfection reagent according to the manufacturer’s instructions.
The expression of Firefly and Renilla luciferases was analysed 48 h
after transfection, according of the manufacturer’s instructions.
Cloning of the human Snail1 promoter (2869/+59) in pGL3 basic
(Promega), was described previously [43]. E-cadherin promoter
were cloned into pGL3-basic (Promega) to generate pGL3-E-
cadherin (2178/+92).
Transfection of small interfering RNA
HUVEC or G361 cells were transiently transfected with an
irrelevant siRNA [44], PARP-1 siRNA or vimentin siRNA
(Thermo Scientific) for 24 h using JetPrime (Polyplus transfection)
according to the manufacturer’s recommendations. At 48 h post-
transfection, the expression of PARP-1, vimentin, Axl, E-cadherin,
Snail1, ILK, b-catenin, pGSK-3b and total-GSK-3b was
measured. Cells were washed twice in phosphate-buffered saline
(PBS) and scraped in Laemmli buffer (1 M Tris, 20% SDS and
10% glycerol) and sonicated. The protein concentration was
determined using the Lowry assay. Levels of b-actin were
monitored as a loading control.
Transfection with GFP-vimentin
We used the GFP-vimentin expression vector supplied by Dr.
Goldman (Department of Cell and Molecular Biology, Chicago,
Figure 8. PARP inhibitors interfere with EndoMT, EMT and vasculogenic mimicry in melanoma cells. Vimentin down-regulation is
pivotal in driving this effect of PARP inhibitors, acting through the ILK/GSk-3b (see the text). While VE-cadherin is upregulated by PARP inhibitors in
endothelial cells, contributing to vascular normalisation, its levels are down-regulated in malignant melanoma cells (Figure 5C). The ultimate reason
for this cell-specific regulation of VE-cadherin expression by PARP is being studying currently in our laboratory.
doi:10.1371/journal.pgen.1003531.g008
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Illinois). For transfection, JetPrime was used according to the
manufacturer’s protocol.
24 h post-tranfection, 5 mM of LiCl (Sigma Aldrich) was added
in MCF7 cells and 48 hours later, the expression of vimentin, ILK,
pGSK-3b, total-GSk-3b, E-cadherin, Snail1 and b-catenin was
measured. In other experiment, co-transfection of GFP-vimentin
and ILK siRNA (Sigma Aldrich) was used the according of the
manufacturer’s protocol. GFP and an irrelevant siRNA [44] were
used as a control.
Migration/invasion assays
HUVEC and B16-F10 cells were cultured on coverslips in six-well
cell culture dishes. Monolayer cultures were stained with Cell-
Tracker Green CMFDA in HUVEC cell (5-chloromethylfluorescein
diacetate) (Invitrogen) according to manufacturer recommendations
or with 49,69-diamidino-2-phenylindole dihydrochloride (DAPI)
(post-fixation). A wound was induced in the confluent monolayer
cultures, and the cultures were then treated with the indicated
inhibitor. The cells were fixed with 3.7% buffered formaldehyde and
then prepared for immunofluorescence. Images were captured using
a confocal microscope (LEICA TCS SP5 Argon Laser 488 nm,
HeNe Laser 543 nm) when the cells were stained with CellTracker
Green CMFDA Abs [522 nm] and Em [529 nm] and Zeiss Axio
Imager A1 microscopy for cells stained with DAPI.
The method used to Wound Healing using a service provided
by Wimasis with permits users to upload their images online at any
time and form anywhere and allows their images to be analyzed
and the results uploaded back to the researcher’s serve.
Scattering assay
Madin-Darby canine kidney (MDCK) cells (1,56104) were
seeded in 12-well tissue culture dish. After 24 h, cells were
transfected with GFP or GFP-vimentin and 1 day after, cells were
incubated with HGF (hepatocyte growth factor, Sigma Aldrich) or
PBS. HGF is a mitogenic growth factor that is well known to
induce the dissociation of islands of cells into individual cells,
termed ‘‘cell scattering’’ or EMT. When inhibitors were used, cells
were preincubated with PARP-1 inhibitor, PJ-34 or Olaparib for
2 h before addition of HGF. After 48 h, representative photo-
graphs were taken at 106 magnification using a Leica Spectral
confocal laser microscope. The results were analyzed using the
MetaMorph image analysis software.
In vitro angiogenesis assay
The effect of PARP inhibitors on the formation of tube-like
structures in Matrigel (BD Biosciences) was determined according
to manufacturer instructions. Briefly, 24-well plates were coated
with 100 ml of BD MatrigelTM Basement Membrane Matrix and
allowed to solidify at 37uC in 5% CO2. Cells were treated with
DPQ (40 mM) or PJ-34 (10 mM). After 22 h of incubation at 37uC
in 5% CO2, the cells were fixed with 3.7% formaldehyde, and
images were acquired using an Olympus CKX41 microscope. The
formation of tube-like structures was then quantified. Each
treatment was performed in triplicate, and the experiment was
independently repeated at least three times.
Matrigel angiogenesis assay in vivo
C57BL/6 mice background (8 weeks old) were subcutaneously
(s.c.) flank-injected with 600 ml of matrigel (BD Biosciences)
supplemented with VEGF (100 ng/ml) (Peprotech) and heparin
(Sigma, 19 U). The negative controls contained heparin alone.
Each group consisted of four animals. After seven days, mice were
sacrificed and matrigel plugs were extracted. The angiogenic
response was evaluated by macroscopic analysis of the plug at
autopsy and by measurement of the hemoglobin (Hb) content
within the pellet of matrigel. Hb was mechanically extracted from
pellets reconstituted in water and measured using the Drabkin
(Sigma-Aldrich) method by spectrophotometric analysis at
540 nm. The values were expressed as optical density (OD)/
100 mg of matrigel.
In vivo bioluminescence assay
This study was performed in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the Bioethical Committee of CSIC. The
protocol was approved by the Committee on the Ethics of Animal
Experiments of the CSIC. All surgery was performed under
isoflurano anesthesia, and every effort was made to minimize
suffering.
Eight-week-old male C57BL/6 albino mice (The Jackson
Laboratories, Bar Harbor, MN, USA) were injected subcutane-
ously with B16-F10-luc-G5 cells (16105) and intravenously with
B16-F10-luc-G5 cells (16105 or 56105). Three times per week
mice were injected intraperitoneally with DPQ dissolved in
phosphate-buffered saline/10% DMSO at a dose of 15 mg/kg
body weight or olaparib at 50 mg/kg. Mice were injected
intraperitoneally with D-luciferin solution dissolved in phos-
phate-buffered saline at a dose of 150 mg/kg body weight. After
5 to 8 minutes, the animals were anesthetized in the dark chamber
using 3% isoflurane in air at 1.5 L/min and O2 at 0.2 L/min/
mouse, and animals were imaged in a chamber connected to a
camera (IVIS, Xenogen, Alameda, CA). Exposure time was 3 min
in large binning, and the quantification of light emission was
performed in photons/second using Living Image software
(Xenogen). Tumor growth was monitored at 0, 2, 7, 14 and 21
days by in vivo imaging and bioluminiscence measurement. After
21 days, mice were sacrificed, and their organs were removed and
stored in buffered formalin (3.7%) until histological staining.
Indirect immunofluorescence
Immunostaining for vimentin, VE-cadherin, pVE-cadherin,
Snail1 and E-Cadherin was performed on cells plated onto
coverslips and grown for 22 h prior to experimental treatments.
The culture medium was removed, and the cells were fixed
(Paraformaldehyde 3%, Sucrose 2% in PBS) for 10 minutes at
room temperature. Permeabilization was performed using 0.2%
Triton X-100 in PBS. The coverslips were rinsed three times in
PBS prior to incubation with primary antibody for 1 h at RT and
then rinsed three times in PBS before incubation with the
secondary antibody. Secondary antibodies were FITC-conjugated
anti-mouse IgG or anti-rabbit (Sigma, St. Louis, MO). Antibodies
were diluted in PBS containing 2% bovine serum albumin.
Nuclear counterstaining with 49,69-diamidino-2-phenylindole di-
hydrochloride (DAPI) was performed after removal of excess
secondary antibody. Slides were prepared using Vectashield
mounting medium (Vector Lab., Inc., Burlingame, CA 94010),
cover slipped and stored in the dark at 4uC. Immunofluorescence
images were obtained in the linear range of detection to avoid
signal saturation using a fluorescent microscope (Zeiss Axio
Imager A1) or confocal microscopy (Leica SP5).
Histological techniques
For conventional morphology, three buffered 4% formaldehyde-
fixed, paraffin-embedded skin longitudinal tissue sections were
stained with periodic acid schiff (PAS) at the end of treatment. The
study was done in blinded fashion on 4-mm sections with light
microscopy. The mitosis and apoptosis cells were assessed by
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examining their number in ten high power field (hpf) at 6006
magnifications. The results were expressed as number of cells per
mm2. For evaluation of blood vessels density, tissue sections of
different groups were dewaxed, hydrated, and heat-treated in 0.01 M
citrate buffer for antigenic unmasking. The rest of the procedure was
carried out using an automatic immunostainer (Autostainer480,
Labvision, Fremont CA, USA). The incubation time with lectin Ulex
europaeus biotin conjugated was 60 min, the dilution was 1:200, and
the streptavidin-biotin-peroxidase method (Master Diagno´stica,
Granada, Spain) with diaminobezidine was used as visualization
system. A millimeter scale in the eyepiece of a microscope BH2
(Olympus) with 406objective was used to count the vessel per mm2
of tissue section. The morphological and immunohistochemistry
study was done in a double-blinded fashion by two pathologists.
Statistical analysis
For data shown in Figure 7 and FigureS7 we have fitted the
values of the average number of tumors per mouse during
carcinogenesis treatment using the Mann-Whitney u-test. Statis-
tical analysis of other experiments used unpaired Student’s t-test.
Supporting Information
Figure S1 PARP inhibitors decrease VEGF-induced tube
formation in HUVECs in vitro and in vivo. Cells were collected
and seeded in Matrigel-coated 48-well plates and then incubated
in the absence (Control) or presence of VEGF and DPQ (40 mM)
or PJ34 (20 mM). After 48 h, the morphological changes of the
cells and any tubes formed were observed and recorded under a
microscope. Micrographs were taken 406. The number of tube
was counted (A) (n = 4), and mean is shown. Bars 6 SEM
(**P,0.01 versus control). After subcutaneous matrigel injection in
the presence and absence of PARP inhibitor DPQ, a decreased in
VEGF-induced in vivo angiogenesis was observed. The formation
of vessel in vivo was assessed after injection of HUVEC with
matrigel plug contains VEGF and heparin. The neovascularizaton
was evaluated by measurement of HB content of matrigel plug.
The histogram represents the mean (n= 4) of the content,
expressed as absorbance (DO)/100 mg of matrigel plug (B).
(TIF)
Figure S2 2D-DIGE (Differential In-Gel Electrophoresis). HU-
VEC were solubilized in 2D-DIGE sample buffer (40 mM Tris,
7 M Urea, 2 M Thiourea, 1% ASB-14), sonicated and then the
concentration was determined using the RC hDC Protein Assay
(Bio- Rad). Fifty mg of protein was then labelled with 400 pmol of
CyDye DIGE Fluor minimal dyes (GE Healthcare) and incubated
on ice in the dark for at least 30 min according to manufacturer
instructions Cy3 (A), Cy5 (B) for samples and Cy2 (C) for internal
control consisting of equal parts of all samples). The reaction was
halted by the addition of 10 mM lysine and incubated on ice for
10 min. Samples were loaded onto IPG strips (7 cm, pH 4–7) (Bio-
Rad) by passive rehydration for 15 h and subjected to isoelectro-
focusing using the PROTEAN IEF Cell System (Bio-Rad)
according to the manufacturer’s protocols. For the second
dimension, strips were loaded on top of 7.5% polyacrylamide gels
at 150 V for 1 h. The 2D gels were then scanned using a Typhoon
Imager (GE Healthcare) at 100 mm resolution with lex/lem of
488/520, 532/580, and 633/670 nm for Cy2, Cy3, and Cy5,
respectively. Image analysis was performed using DeCyder 6.5
software (GE Healthcare) as described in the user manual. Six
independent experiments were performed for each experimental
setup. Briefly, the differential in-gel analysis (DIA) module was
used for spot detection, spot volume quantification and volume
ratio normalization of different samples in the same gel (D).
Differentially expressed spots were considered for identification
based upon the fold change (.1.1) and the t-test (*P,0.05). (E) The
Image analysis DeCyder Sofware indicated those differential spots
detected in HUVEC treated with DPQ cells that were subsequently
identified.
(TIF)
Figure S3 PARP inhibition reduced the expression of Vimentin
and Snail1 and up-regulates E-cadherin murine melanoma cells.
Cells were treated with either of the PARP inhibitors DPQ (40 mM)
(not shown), PJ34 at 10 mM or KU0058948 (100 nM) during
22 hours. IF (A), western-blot (B) or qPCR (C) were performed to
evaluate the impact of PARP inhibition on EMTmarkers. *P,0.05,
***P,0.001 PARP Inhibitor groups versus the control. b-actin was
used as internal controls for protein loading. Luciferase activity (D)
was determined after transfecting the constructions into the B16-F10
cells. *P,0.05 control versus DPQ. The expression of Firefly and
Renilla luciferases was analyzed 48 h after transfection, according of
the manufacturer’s instructions.
(TIF)
Figure S4 Western-blot (A) and immunofluorescence (B) of
PARP activity inhibition in G361cells treated with the PARP-1
inhibitor, DPQ.
(TIF)
Figure S5 Development of subcutaneous xenografts of mela-
noma is reduced by treatment with the PARP inhibitor DPQ.
(A) C57BL/6 albino mice (Jackson Laboratories, Philadelphia,
USA), were inoculated with B16-F10-luc cells as explained in
Methods. Localization and intensity of luciferase expression
was monitored by in vivo bioluminescence imaging. Quantitation
of luciferase activity over time in photons/s, is represented in the
color bar. Vehicle (n = 4), DPQ (n= 4). **P,0.01; ***P,0.001.
(B) Ex-vivo photon emission: treatment with the PARP inhibitor
DPQ reduced lung and extra-pulmonary melanoma-induced
metastasis.
(PDF)
Figure S6 Treatment with the PARP inhibitor olaparib
decreased metastatic spread of melanoma cells. C57BL/6 mice
were inoculated with B16-F10-luc cells a treated with the PARP
inhibitor olaparib (50 mg/kg) as explained in Methods. Results
obtained on the 17th day are shown for quantitation. *P,0.05
olaparib versus control using the Mann-Whitney u-test.
(TIF)
Figure S7 Cell proliferation and apoptosis are not affected by
PARP inhibition in metastasis. Mitosis and apoptosis were evaluated
in histological metastasis slides using morphological criteria and
evaluated in a blind observation by two different pathologists.
(TIF)
Figure S8 IHC evaluation of PARP-1 and EMT markers in
human melanoma tissue array. Expression of PARP-1 and EMT
markers in nodular and metastatic human melanoma. PARP-1
expression correlates with vimentin in nodular and metastatic
melanoma. Snail1 and E-cadherin expression do not correlate
with PARP-1 positivity.
(TIF)
Table S1 Results for all the different markers are presented.
Samples were analyzed in a blind fashion by two different pathologists.
(TIF)
Table S2 Quantitation of western-blots. All western blots shown
have been quantified using Quantity One software from Bio-Rad.
(PDF)
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